360 filings
Page 11 of 18
S-8
k7rw5cd tr
15 Mar 18
Registration of securities for employees
12:00am
8-K
zwp7lhylhpom0
14 Mar 18
Miragen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
12:00am
8-K
hxx 3vmps
28 Feb 18
Other Events
12:00am
424B5
zqh84pltce1s
9 Feb 18
Prospectus supplement for primary offering
12:00am
8-K
ez3lb4w5wiv ho
9 Feb 18
Miragen Therapeutics, Inc. Prices Public Offering of Common Stock
12:00am
8-K
xlrp5wzhst
5 Feb 18
Miragen Therapeutics Presents New Data from Phase 1 Clinical Trial OFMRG-106
12:00am
424B5
m5jcjixtufipq23e3ez
5 Feb 18
Prospectus supplement for primary offering
12:00am
8-K
u8ovneefqh9w6i no
5 Jan 18
Miragen Therapeutics Expands Board of Directors with Appointment
12:00am
8-K
dtmwqvo87muf77i0
11 Dec 17
Other Events
12:00am
D
1ht txsp81b3pf
22 Nov 17
$172.29K in options / securities to be acquired, sold $172.29K, 1 investor
12:00am
CT ORDER
ee7ydebhsf1b gmw12i
20 Nov 17
Confidential treatment order
12:00am
8-K
vhuhyfw
15 Nov 17
Entry into a Material Definitive Agreement
12:00am
CT ORDER
wcgoiefw
14 Nov 17
Confidential treatment order
12:00am
8-K
b43z4dx70anf8
8 Nov 17
Miragen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
12:00am
8-K
itkea trb4
13 Oct 17
Other Events
12:00am
8-K
sa0357z5 j5u
11 Sep 17
Miragen Therapeutics Presents New MRG-201 Preclinical Data for Inhaled MICRORNA-29 Mimic Targeting Pulmonary Fibrosis
12:00am
CT ORDER
o5650mkok1wfh5sc
28 Aug 17
Confidential treatment order
12:00am
8-K
ank6mn xf61o1ud
11 Aug 17
Miragen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
12:00am